Pfizer (NYSE:PFE) gained EU antitrust approval for its $43 billion acquisition of Seagen, a cancer drug maker. This acquisition, announced in March, is Pfizer's largest recent purchase, fueled by the financial success of its COVID-19 vaccines and treatments. The European Commission found no significant competition or pricing concerns in the 27-country European Union, stating that the merger doesn't raise competition issues.
Seagen, based in Washington, specializes in antibody-drug conjugates designed to selectively destroy cancer cells, sparing healthy ones.
Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
Seagen, based in Washington, specializes in antibody-drug conjugates designed to selectively destroy cancer cells, sparing healthy ones.
Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.